KDIGO issued a 2026 anemia of chronic kidney disease (CKD) guideline to help healthcare providers and patients make informed management decisions.

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Well, the first step is diagnosis. We have ...

dementia Additional studies are needed to determine whether anemia itself is a risk factor for dementia in the CKD population. Anemia in patients with chronic kidney disease (CKD) portends an ...

Ziltivekimab, an anti-IL-6 ligand antibody, increases iron and other anemia parameters in patients with chronic kidney disease. Ziltivekimab, a novel anti-IL-6 ligand antibody, improves ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Let's start with what causes anemia of ...

We observed that anemia and chronic kidney disease are two frequent conditions among stroke patients. Anemia was independently associated with a decreased one-year survival. Although GFR was ...

Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be a better adjunct treatment to reduce anemia risk than glucagon-like peptide 1 receptor agonists (GLP-1 RAs) for patients with type 2 diabetes ...

Chronic kidney disease (CKD) is frequently complicated by anaemia, predominantly due to an inadequate production of erythropoietin combined with disruptions in iron metabolism and chronic inflammation ...

SGLT2 inhibitors may be a useful adjunct therapy to reduce anemia risk in patients with type 2 diabetes and early CKD. Anemia risk is lower among patients receiving SGLT2 inhibitors (SGLT2i) compared ...

GREENFIELD, Ind.--(BUSINESS WIRE)-- Today, Elanco Animal Health Incorporated (NYSE: ELAN) announced that the first shipments of Varenzin™-CA1 (molidustat oral suspension), conditionally approved by ...